vs

Side-by-side financial comparison of Progressive Corporation (PGR) and Walgreens Boots Alliance (WBA). Click either name above to swap in a different company.

Walgreens Boots Alliance is the larger business by last-quarter revenue ($39.0B vs $22.7B, roughly 1.7× Progressive Corporation). Progressive Corporation runs the higher net margin — 13.0% vs -0.4%, a 13.4% gap on every dollar of revenue. On growth, Progressive Corporation posted the faster year-over-year revenue change (12.2% vs 7.2%). Progressive Corporation produced more free cash flow last quarter ($3.0B vs $336.0M). Over the past eight quarters, Progressive Corporation's revenue compounded faster (14.9% CAGR vs 4.9%).

The Progressive Corporation is an American insurance company. Progressive is currently the #2 auto insurer in the United States behind State Farm. The company was co-founded in 1937 by Jack Green and Joseph M. Lewis, and is headquartered in Mayfield, Ohio. The company insures passenger vehicles, motorcycles, recreational vehicles (RVs), trailers, boats, personal water craft (PWC), and commercial vehicles. Progressive also provides home, life, pet, and other types of insurance through select c...

Walgreens Boots Alliance, Inc. (WBA) was an American multinational holding company headquartered in Deerfield, Illinois. The company was formed on December 31, 2014, after Walgreens bought the 55% stake in Alliance Boots that it did not already own. The total price of the acquisition was $4.9 billion in cash and 144.3 million common shares with fair value of $10.7 billion. Walgreens had previously purchased 45% of the company for $4.0 billion and 83.

PGR vs WBA — Head-to-Head

Bigger by revenue
WBA
WBA
1.7× larger
WBA
$39.0B
$22.7B
PGR
Growing faster (revenue YoY)
PGR
PGR
+4.9% gap
PGR
12.2%
7.2%
WBA
Higher net margin
PGR
PGR
13.4% more per $
PGR
13.0%
-0.4%
WBA
More free cash flow
PGR
PGR
$2.7B more FCF
PGR
$3.0B
$336.0M
WBA
Faster 2-yr revenue CAGR
PGR
PGR
Annualised
PGR
14.9%
4.9%
WBA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PGR
PGR
WBA
WBA
Revenue
$22.7B
$39.0B
Net Profit
$3.0B
$-175.0M
Gross Margin
16.7%
Operating Margin
16.2%
0.1%
Net Margin
13.0%
-0.4%
Revenue YoY
12.2%
7.2%
Net Profit YoY
25.3%
-150.9%
EPS (diluted)
$5.01
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PGR
PGR
WBA
WBA
Q4 25
$22.7B
Q3 25
$22.5B
Q2 25
$22.0B
$39.0B
Q1 25
$20.4B
$38.6B
Q4 24
$20.3B
$39.5B
Q3 24
$19.7B
$37.5B
Q2 24
$18.1B
$36.4B
Q1 24
$17.2B
$37.1B
Net Profit
PGR
PGR
WBA
WBA
Q4 25
$3.0B
Q3 25
$2.6B
Q2 25
$3.2B
$-175.0M
Q1 25
$2.6B
$-2.9B
Q4 24
$2.4B
$-265.0M
Q3 24
$2.3B
$-3.0B
Q2 24
$1.5B
$344.0M
Q1 24
$2.3B
$-5.9B
Gross Margin
PGR
PGR
WBA
WBA
Q4 25
Q3 25
Q2 25
16.7%
Q1 25
18.0%
Q4 24
17.2%
Q3 24
16.7%
Q2 24
17.8%
Q1 24
19.0%
Operating Margin
PGR
PGR
WBA
WBA
Q4 25
16.2%
Q3 25
14.8%
Q2 25
18.1%
0.1%
Q1 25
15.9%
-14.4%
Q4 24
14.6%
-0.6%
Q3 24
14.9%
-2.6%
Q2 24
10.3%
0.3%
Q1 24
17.1%
-35.5%
Net Margin
PGR
PGR
WBA
WBA
Q4 25
13.0%
Q3 25
11.6%
Q2 25
14.4%
-0.4%
Q1 25
12.6%
-7.4%
Q4 24
11.6%
-0.7%
Q3 24
11.8%
-8.0%
Q2 24
8.0%
0.9%
Q1 24
13.5%
-15.9%
EPS (diluted)
PGR
PGR
WBA
WBA
Q4 25
$5.01
Q3 25
$4.45
Q2 25
$5.40
$-0.20
Q1 25
$4.37
$-3.30
Q4 24
$4.01
$-0.31
Q3 24
$3.97
$-3.48
Q2 24
$2.48
$0.40
Q1 24
$3.94
$-6.85

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PGR
PGR
WBA
WBA
Cash + ST InvestmentsLiquidity on hand
$10.0B
$830.0M
Total DebtLower is stronger
$7.4B
Stockholders' EquityBook value
$30.3B
$7.2B
Total Assets
$123.0B
$69.4B
Debt / EquityLower = less leverage
1.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PGR
PGR
WBA
WBA
Q4 25
$10.0B
Q3 25
$1.5B
Q2 25
$2.1B
$830.0M
Q1 25
$2.6B
$1.1B
Q4 24
$615.0M
$1.2B
Q3 24
$757.0M
$3.1B
Q2 24
$733.0M
$703.0M
Q1 24
$1.3B
$668.0M
Total Debt
PGR
PGR
WBA
WBA
Q4 25
Q3 25
Q2 25
$7.4B
Q1 25
$8.0B
Q4 24
$8.1B
Q3 24
$9.6B
Q2 24
Q1 24
Stockholders' Equity
PGR
PGR
WBA
WBA
Q4 25
$30.3B
Q3 25
$35.4B
Q2 25
$32.6B
$7.2B
Q1 25
$29.0B
$7.1B
Q4 24
$25.6B
$9.9B
Q3 24
$27.2B
$10.4B
Q2 24
$23.3B
$13.6B
Q1 24
$21.8B
$13.5B
Total Assets
PGR
PGR
WBA
WBA
Q4 25
$123.0B
Q3 25
$121.5B
Q2 25
$115.5B
$69.4B
Q1 25
$111.4B
$70.2B
Q4 24
$105.7B
$78.5B
Q3 24
$105.2B
$81.0B
Q2 24
$97.9B
$83.0B
Q1 24
$94.1B
$84.2B
Debt / Equity
PGR
PGR
WBA
WBA
Q4 25
Q3 25
Q2 25
1.03×
Q1 25
1.13×
Q4 24
0.81×
Q3 24
0.92×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PGR
PGR
WBA
WBA
Operating Cash FlowLast quarter
$3.2B
$584.0M
Free Cash FlowOCF − Capex
$3.0B
$336.0M
FCF MarginFCF / Revenue
13.4%
0.9%
Capex IntensityCapex / Revenue
0.5%
0.6%
Cash ConversionOCF / Net Profit
1.07×
TTM Free Cash FlowTrailing 4 quarters
$17.2B
$580.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PGR
PGR
WBA
WBA
Q4 25
$3.2B
Q3 25
$5.2B
Q2 25
$4.0B
$584.0M
Q1 25
$5.1B
$-199.0M
Q4 24
$3.0B
$-140.0M
Q3 24
$4.6B
$1.3B
Q2 24
$3.3B
$604.0M
Q1 24
$4.2B
$-637.0M
Free Cash Flow
PGR
PGR
WBA
WBA
Q4 25
$3.0B
Q3 25
$5.1B
Q2 25
$3.9B
$336.0M
Q1 25
$5.1B
$-418.0M
Q4 24
$2.9B
$-424.0M
Q3 24
$4.6B
$1.1B
Q2 24
$3.2B
$327.0M
Q1 24
$4.2B
$-989.0M
FCF Margin
PGR
PGR
WBA
WBA
Q4 25
13.4%
Q3 25
22.8%
Q2 25
17.9%
0.9%
Q1 25
24.9%
-1.1%
Q4 24
14.3%
-1.1%
Q3 24
23.1%
2.9%
Q2 24
17.6%
0.9%
Q1 24
24.3%
-2.7%
Capex Intensity
PGR
PGR
WBA
WBA
Q4 25
0.5%
Q3 25
0.3%
Q2 25
0.5%
0.6%
Q1 25
0.3%
0.6%
Q4 24
0.5%
0.7%
Q3 24
0.3%
0.7%
Q2 24
0.4%
0.8%
Q1 24
0.3%
1.0%
Cash Conversion
PGR
PGR
WBA
WBA
Q4 25
1.07×
Q3 25
1.99×
Q2 25
1.27×
Q1 25
2.00×
Q4 24
1.28×
Q3 24
1.97×
Q2 24
2.24×
1.76×
Q1 24
1.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PGR
PGR

Other$11.9B52%
Commercial Lines Segment$10.9B48%
Other Indemnity$2.0M0%

WBA
WBA

Pharmacy$24.4B63%
Retail$6.3B16%
International Reportable Segment$6.2B16%
US Healthcare$2.1B5%

Related Comparisons